We show you our most important and recent visitors news details Johnson & Johnson’s single-shot COVID-19 vaccine is safe and effective, confirms FDA in the following article
Hind Al Soulia - Riyadh - NEW YORK — In an analysis released on Wednesday, the US Food and Drug Administration said the Johnson & Johnson COVID-19 vaccine has met the requirements for emergency use authorization.
The efficacy of the Johnson & Johnson vaccine against moderate to severe/critical COVID-19 across all geographic areas was 66.9 percent at least 14 days after the single dose vaccination and 66.1 percent at least 28 days after vaccination, a new analysis meant to brief the FDA's Vaccines and Related Biological Products Advisory Committee said.
"There were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection," the analysis said.
In a briefing document, the FDA said that it has reviewed the data for the vaccine and has determined that it is "consistent with the recommendations set forth in FDA's guidance Emergency Use Authorization for Vaccines to Prevent COVID-19."
An independent group of FDA advisers, the Vaccines and related Biological Products Advisory Committee, will consider the documents and make a recommendation about whether the COVID-19 vaccination should be authorized. The committee meets on Friday. — Courtesy CNN
These were the details of the news Johnson & Johnson’s single-shot COVID-19
vaccine is safe and effective, confirms FDA for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Saudi Gazette and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.